Clinical Trial Update: Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating rifaximin for bloating in cystic fibrosis patients has been withdrawn. The document records the withdrawal of this clinical trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Cystic Fibrosis, Abdominal Pain | Phase 2, Phase 3 | Status: WITHDRAWN